bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wire • 12/08/24
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb LevelsBusiness Wire • 12/07/24
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access ModelBusiness Wire • 12/04/24
My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 BuysSeeking Alpha • 11/20/24
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding OptionsBenzinga • 11/15/24
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 GuidanceBusiness Wire • 11/14/24
After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)Zacks Investment Research • 11/08/24
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results CallBusiness Wire • 11/06/24
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wire • 11/05/24
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025Business Wire • 09/24/24
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-QBusiness Wire • 09/13/24
My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 BuysSeeking Alpha • 08/28/24